Russell Investments Group Ltd. Acquires 69,559 Shares of Sanofi $SNY

Key Points

• Russell Investments Group Ltd. increased its stake in Sanofi by 18.1%, acquiring a total of 453,236 shares, valued at approximately $25 million.
• Institutional investors currently hold about 14.04% of Sanofi's shares, with several firms, including Cardinal Capital Management and AdvisorNet Financial Inc., also increasing their positions in the first quarter.
• Sanofi reported $0.90 EPS for the last quarter, missing expectations, although it achieved a revenue of $11.34 billion, exceeding estimates of $9.91 billion.

Russell Investments Group Ltd. increased its position in Sanofi (NASDAQ:SNY - Free Report) by 18.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 453,236 shares of the company's stock after buying an additional 69,559 shares during the period. Russell Investments Group Ltd.'s holdings in Sanofi were worth $25,136,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Accent Capital Management LLC bought a new position in Sanofi during the first quarter worth $29,000. Eastern Bank grew its stake in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the last quarter. Finally, Brentview Investment Management LLC bought a new stake in Sanofi during the 1st quarter worth approximately $42,000. Institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on SNY. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $62.00.

Sanofi Stock Performance

Shares of SNY traded up $0.07 during mid-day trading on Monday, reaching $49.84. The company's stock had a trading volume of 3,945,271 shares, compared to its average volume of 2,659,869. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The business has a 50-day simple moving average of $48.57 and a two-hundred day simple moving average of $51.78. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $122.38 billion, a P/E ratio of 11.98, a PEG ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The company's revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the business earned $1.73 earnings per share. As a group, equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.